Status:
UNKNOWN
Biomarker Discovery and Validation in Lung Cancer
Lead Sponsor:
Dr. Guy Berchem
Collaborating Sponsors:
Integrated Biobank of Luxembourg
Centre Hospitalier du Luxembourg
Conditions:
Lung Cancer
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Lung cancer is responsible for the most deaths due to cancer each year in both men and women worldwide and once diagnosed, the 10 year survival rate is poor (\<15%). This poor prognosis is based in la...
Detailed Description
The primary objective of this study is to discover and validate molecular biomarkers for lung cancer. Lung cancer remains the leading cause of cancer death in industrialized countries. Most patients ...
Eligibility Criteria
Inclusion
- Patients with a suspected or confirmed diagnosis of lung cancer, whether or not scheduled for lesion biopsy, thoracentesis or surgical resection of their tumor
Exclusion
- Pregnant women
- Minors (subjects less than 18 years of age)
- Prisoners
- Subjects unable to consent for themselves
Key Trial Info
Start Date :
October 14 2009
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 1 2020
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT01147562
Start Date
October 14 2009
End Date
October 1 2020
Last Update
February 1 2019
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Centre Hospitalier de Luxembourg (CHL)
Luxembourg, Luxembourg, 1210
2
Clinique Sainte Thérèse (Zithaklinik)
Luxembourg, Luxembourg, L-2763